Elemosho Abdulaziz, Kluemper Jude C, Pfahl Emily, Mitchell Kerry-Ann S
Department of Plastic & Reconstructive Surgery, The Ohio State University Wexner College of Medicine, Columbus, OH.
J Craniofac Surg. 2025;36(1):115-118. doi: 10.1097/SCS.0000000000010728. Epub 2024 Oct 15.
Hydroxyapatite bone cement (HABC) has evolved to have diverse applications in craniofacial reconstruction. This ranges from filling cranial defects to secondary contouring of residual defects after primary surgeries. This study aims to determine patient outcomes after reconstruction with HABCs.
A systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. PubMed, Embase, Web of Science, and Cochrane Library databases were queried. The results were limited to English-language literature with extractable data on HABC for craniofacial reconstruction.
A total of 1983 patients were included in the final analysis from 35 studies. HABCs were mostly used for large defect cranioplasty (21.5%), retrosigmoid (44.6%) and translabyrinthine cranioplasty (8.9%), and correction of residual craniofacial defects after congenital craniofacial surgeries (25%). The rates of cerebrospinal fluid (CSF) leak and infection/explantation were 0% and 7.5% [95% CI: 2.4-11.8] for large defect cranioplasty and 0.8% [0.03-2.07] and 1.5% [95% CI: 0.92-3.3] for retrosigmoid cranioplasty, respectively. The infection/explantation rate was 6.2% [95% CI: 2.6-18.7] for HABCs in the correction of residual craniofacial defects after congenital craniofacial surgeries. The total reoperation rates were 20.4% % [95% CI: 4.8-11.8] for large defect cranioplasty and 12% [95% CI: 3.3-15.3] for correction of residual defects after congenital craniofacial surgeries. Aesthetic satisfaction rates were 93.1% [95% CI: 90.3-98.8] for large defect cranioplasty, 99.4% [95% CI 97.2-99.9] for retrosigmoid cranioplasty, and 92.6% [95% CI: 83.3-95.8] for HABC use in the correction of residual craniofacial defects after congenital craniofacial surgeries.
HABC is versatile and associated with a high level of patient reported aesthetic satisfaction after cranioplasty and may have a comparably lower complication profile than those of most other alloplastic materials.
羟基磷灰石骨水泥(HABC)已在颅面重建中得到广泛应用。其应用范围从填充颅骨缺损到初次手术后残余缺损的二次轮廓塑形。本研究旨在确定使用HABC进行重建后的患者预后。
根据系统评价和荟萃分析的首选报告项目(PRISMA)指南进行系统评价和荟萃分析。检索了PubMed、Embase、科学网和考克兰图书馆数据库。结果仅限于有关于HABC用于颅面重建的可提取数据的英文文献。
最终分析纳入了35项研究中的1983例患者。HABC主要用于大型缺损颅骨成形术(21.5%)、乙状窦后颅骨成形术(44.6%)和经迷路颅骨成形术(8.9%),以及先天性颅面手术后残余颅面缺损的矫正(25%)。大型缺损颅骨成形术的脑脊液漏和感染/植入率分别为0%和7.5%[95%CI:2.4 - 11.8],乙状窦后颅骨成形术的感染/植入率分别为0.8%[0.03 - 2.07]和1.5%[95%CI:0.92 - 3.3]。先天性颅面手术后使用HABC矫正残余颅面缺损的感染/植入率为6.2%[95%CI:2.6 - 18.7]。大型缺损颅骨成形术的总再次手术率为20.4%[95%CI:4.8 - 11.8],先天性颅面手术后残余缺损矫正的总再次手术率为12%[95%CI:3.3 - 15.3]。大型缺损颅骨成形术的美学满意率为93.1%[95%CI:90.3 - 98.8],乙状窦后颅骨成形术的美学满意率为99.4%[95%CI 97.2 - 99.9],先天性颅面手术后使用HABC矫正残余颅面缺损的美学满意率为92.6%[9&CI:83.3 - 95.8]。
HABC用途广泛,颅骨成形术后患者报告的美学满意率较高,与大多数其他异体材料相比,其并发症发生率可能相对较低。